Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018

December 14, 2018 – EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its December 2018 meeting. Two orphan medicines1 received a positive opinion from the Committee: Ropeginterferon alfa-2b, for the treatment of polycythaemia vera without symptomatic splenomegaly, and Treosulfan, for the conditioning treatment prior to allogeneic haematopoietic stem cell transplantation. The CHMP recommended granting a … (leggi tutto)